Integra LifeSciences Holdings Corporation reports developments as a global medical technology company focused on neurosurgery and tissue reconstruction. News commonly covers quarterly financial results, revenue guidance, operational execution, supply reliability, quality-management work and product availability across its medical technology portfolio.
Company updates also include clinical evidence and medical-conference activity for wound reconstruction products such as PriMatrix Dermal Scaffold, Integra Dermal Matrices, Cytal Wound Matrix, MicroMatrix and AmnioExcel. Recurring corporate topics include leadership appointments, investor conference presentations, manufacturing progress and segment activity within Codman Specialty Surgical and Tissue Technologies.
Integra LifeSciences (IART) enrolled the 100th patient in its AERA Pediatric Registry, which is evaluating the AERA balloon dilation system.
Launched in July 2025, the prospective, multicenter observational registry plans to enroll 300 patients ages eight and older with obstructive Eustachian tube dysfunction at U.S. sites. It is designed to gather evidence on AERA’s clinical performance in routine care. AERA received FDA clearance for use in patients ages eight and older in December 2023.
Integra LifeSciences (IART) will feature liver surgery education and technology at ACS Clinical Congress 2026, held September 26–29.
The Washington, D.C., program marks 20 years of CUSA technology in the company's portfolio. Surgeon-led presentations and discussions will feature the CUSA Clarity Ultrasonic Surgical Aspirator System and MicroFrance laparoscopic instruments. Attendees can visit Booth 428 or attend the company's Innovation Theater presentations.
Integra LifeSciences (IART) will present at the 2026 Wells Fargo Healthcare Conference on September 9, 2026, at 2:15 p.m. ET, and at the 2026 Morgan Stanley Healthcare Conference on September 15, 2026, at 4:05 p.m. ET.
Presenters include the chief financial officer, chief commercial officer, and the chairman and chief executive officer. A live webcast of both presentations will be accessible through the company’s investor relations website under Events & Presentations.
Integra LifeSciences (Nasdaq:IART) reported second quarter 2026 revenue of $418.8 million, up 0.8% reported and 0.7% organic year over year. GAAP EPS was $0.06, versus a loss of $(6.31) a year ago, while adjusted EPS rose to $0.56 from $0.45.
GAAP gross margin improved to 52.5% and adjusted gross margin to 61.3%. Adjusted EBITDA reached $78.4 million (18.7% margin). Specialty Surgery revenue grew 1.7% to $309.3 million, while Tissue Reconstruction declined 1.9% to $109.5 million. Operating cash flow was $22.8 million, net debt was $1.6 billion, and liquidity totaled about $496 million.
For Q3 2026, Integra expects revenue of $410–$425 million and adjusted EPS of $0.53–$0.61. Full‑year reported revenue guidance was slightly reduced to $1.654–$1.695 billion for FX, while organic growth guidance of 0.8%–3.3% and adjusted EPS of $2.40–$2.50 were reaffirmed. The company also initiated production at its Braintree facility ahead of the planned Q4 SurgiMend relaunch.
Integra LifeSciences (NASDAQ: IART) will release its second quarter 2026 financial results on Wednesday, July 29, 2026, before the market opens. Management will host an earnings conference call at 8:30 a.m. ET, with a live webcast and replay available in the Investors section of the company’s website.
Integra LifeSciences (Nasdaq:IART) appointed Topaz Kirlew as corporate vice president and chief regulatory officer, leading global regulatory affairs and strategy.
She previously served as interim regulatory leader, overseeing compliance, submissions, and risk mitigation, and brings over 35 years of healthcare and medical technology experience across regulatory, quality, operations, clinical, and laboratory roles.
Integra LifeSciences (Nasdaq:IART) announced key leadership appointments in its commercial organization to support long-term growth and customer focus.
Robert T. Davis Jr. becomes EVP, Tissue Reconstruction and Distributed Technologies; Christopher Kilburn-Peterson is promoted to corporate VP and president, Tissue Reconstruction; Harvinder Singh becomes EVP and president, Specialty Surgery, while international leaders now report to chief commercial officer Mike McBreen.
Integra LifeSciences (Nasdaq:IART) announced that Bob Davis, executive vice president and president Tissue Reconstruction, will present at the 2026 Truist Securities MedTech Conference on June 16, 2026, at 3:00pm ET.
A live webcast of the presentation will be available on the company’s investor relations website under Events & Presentations.
Integra LifeSciences (Nasdaq:IART) announced that chief financial officer Lea Knight will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 10:30am ET.
A live webcast of the presentation will be available on the company’s investor relations website under Events & Presentations.
Integra LifeSciences (Nasdaq: IART) announced that CFO Lea Knight will present at the BofA Securities 2026 Health Care Conference on May 12, 2026 at 4:20pm PT. A live webcast will be available on the Integra investor relations site under Events & Presentations.